Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Yammer who wrote (1001)	1/8/1998 6:55:00 AM
From: Zvi Yammer	Read Replies (2) \| Respond to of 2742

Annual Meeting Recap. From where I was sitting here's how it looks. 1. Don't know if this is relevant, but, Dr. Grausz seems to be missing in action. In an off to the side conversation Dr. Grausz was descriped as a thrill seeker. In my opinion he got in over his head in some unknown situation and has a lot more problems than just the 250k he owes CIST. We were not told anything about that negotiation but, it is just another uncertainty. 2. Robert Naismith is a director and Steven Simes is not. They didn't say why Simes is not there anymore. I asked Naismith about why he took CIST on as a client. The only solid answer seemed to be that because they had money. 3. There are a number of small "trials" underway. I think what CIST is doing is trying to spend a little money on each of a few different possible uses of IL1 and Anti-IL1. This to test thier hypothesis before committing money to any longer range study. 4. Important events. The "longitudinal Preclinincal Study" of the periodontal diagnostic test has been completed. 70 patients were tested for periodontitis vs. probing the depth of the gum pocket. Results should be expected by month end. New test for "wound healing" theraputic. This would be important for people like diabetics. As explained IL1 is found where there is inflammation. The body needs to inflame an area so would healing can begin. If the inflammation does not start niether would wound healing. So if IL-1 can instigate the inflammaton it can help initiate wound healing. Anti-IL1 theraputics.. Can't really explain this but there is some tests beginning to prevent IL-1.... 5. Toxicity. The major drawback to IL-1 is that it is Toxic. however, Dr. Edelman was quick to explain, that by "encapsulatng" the IL-1 and releasing it in lower doses it remained local to the area being treated. It did not "leak" into the body and was therefore, not toxic. I was very pleased that Dr. Edelman jumped in to answer this question. It was a strong sign of his dedication to the company and the underlying usage of IL-1, even after years of dissapointment. 6. Novavax. A chart was shown of the Novavax flu vaccine alone and with IL-1. The graph showed major increases of the "titer" levels starting after 5 days. After about 20 days the Novavvax+ IL1 was head and shoulders above all other methods. Don't exactly know what it all means just tryingto recall what was said. 7. Here is some encouraging news. The Preferred stock motion was Shot Down. Why is this important. Well it showed the board that there are interested stockholders that will not allow this company to be anything but interested in the shareholders rights to capital gains. There were 18.7 million shares represented at the meeting. This out of some 27 million outstanding. The Preferred stock item was shot down by 6.2 million "no" votes by broker held stock. Well I hope I've got this right. The only thing else is that the meeting was nicely attended. So there are still people very interested in seeing this thing work, regardless of whether or not the stock actually trades. Bye Zvi New Assay kits.. these sales are minimal but the margins are high so the combination of interest on the 6 mil cash plus the margins on the Assay kits help finance the operation and protect the basic cash.